[{"id":"fea520a7-4eba-4fdf-b9d4-98fbf0b1455e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03814447","created_at":"2021-01-18T18:50:52.538Z","updated_at":"2024-07-02T16:36:26.671Z","phase":"Phase 1","brief_title":"The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer","source_id_and_acronym":"NCT03814447","lead_sponsor":"Shanghai 6th People's Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • anti- MESO CAR-T cells • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 08/16/2019","start_date":" 08/16/2019","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2021-08-10"},{"id":"d807f944-6769-4d81-ab96-ee3a7e16288c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03799913","created_at":"2021-01-29T07:18:35.470Z","updated_at":"2024-07-02T16:37:00.741Z","phase":"Phase 1","brief_title":"MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer","source_id_and_acronym":"NCT03799913","lead_sponsor":"Zhejiang University","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • anti- MESO CAR-T cells"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 04/10/2019","start_date":" 04/10/2019","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 04/01/2022","study_completion_date":" 04/01/2022","last_update_posted":"2019-04-10"}]